In Vitro and in Vivo Deposition of Drug Particles Inhaled from Pressurized Aerosol and Dry Powder Inhaler

Vidgrén, M.; Kärkkäinen, Anna‐Mari; Karjalainen, Panu; Nuutinen, Juhani; Paronen, Petteri

doi:10.3109/03639048809152038

Cited by 20 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agents for MDI administration are presented in a compact aerosol container allowing patients to deliver an accurate dose of the drug through a metering valve during inspiration (Vidgren et al 1988). Adaptation of MDI to use in horses led to the development of 2 systems.…”

Section: Metered-dose Inhalers (Mdi)mentioning

confidence: 99%

Inhalation therapy of equine respiratory disorders

Duvivier

Votion

Roberts

et al. 1999

Equine Veterinary Education

View full text Add to dashboard Cite

Section: Metered-dose Inhalers (Mdi)mentioning

confidence: 99%

Inhalation therapy of equine respiratory disorders

Duvivier

Votion

Roberts

et al. 1999

Equine Veterinary Education

View full text Add to dashboard Cite

“…Fractional percentage deposition of disodium crornoglycate from 4 commercial DPIs (Vidgren et al 1988). …”

Section: Upper Lungsmentioning

confidence: 99%

“…1, Vidgren et al 1988) The reason for low pulmonary drug deposition in such DPI systems is considered to be probably due to inefficient deagglomeration of fine drug particles from coarser carrier lactose particles, which are required partly in order to optimize removal of powder from the DPI device on inspiration.…”

Section: Introductionmentioning

confidence: 99%

Performance-Modifying Influences in Dry Powder Inhalation Systems

Staniforth

1995

Aerosol Science and Technology

View full text Add to dashboard Cite

Although dry powder inhaler (DPI) systems offer many advantages over conventional pressurized metered dose aerosols for therapeutic use, there are a number of formulation-related aspects of functionality which can significantly reduce DPI performance. A general introduction is provided to the physical requirements for preparation of efficient and effective therapeutic aerosols and dry powder inhaler systems in particular. Of a number of important DPI design factors highlighted in the introduction, the present study concentrates on two specific ex vivo performance-modifying influences of particle characteristics used in dry powder inhalers. Firstly, powder entrainment characteristics were studied using a model system and it was found that particle-entrainment tube (device) interactions were of two main types, depending on whether coarse or fine lactose particles were involved. In the case of coarse particles (in the range 90-180 pm), entrainment was found to depend on mean linear air velocity (in the range 5-15 ms-' ) and tube diameter. For fine particles (in the range 63-90 pm), entrainment was found to be dependent on both tube diameter and pressure drop at the site of entrainment. Further, in the case of lactose carrier particles > 90 pm, entrainment was found to be complete in a small velocity spread, unlike the behavior of finer particles ( < 90 pm). Secondly, powder blend homogeneity/stability was found to be a function of the number and nature of the contacting surfaces. Optimum homogeneity of lactose/salbutamol blends was achieved with single contact surface blending. Blends were destabilized by contact with dissimilar second contact surfaces.

show abstract

“…There is a suggestion from the available data that overall efficiency of delivery may be somewhat lower with dry powder inhalers compared to MDIs in that up to twice as much nominal dose delivered from the inhaler may be needed for an equivalent clinical result. Limited data are available on dose distribution from the use of dry powder inhalers (Newman et al, 1988;Vidgren et al, 1988Vidgren et al, , 1990. One paper (Vidgren et al, 1988), employing a radiolabel on an altered form of dry powder (spray dry technique), indicated a slightly improved dose distribution with a dry powder inhaler.…”

Section: B) Dry Powder Inhalersmentioning

confidence: 96%

“…Limited data are available on dose distribution from the use of dry powder inhalers (Newman et al, 1988;Vidgren et al, 1988Vidgren et al, , 1990. One paper (Vidgren et al, 1988), employing a radiolabel on an altered form of dry powder (spray dry technique), indicated a slightly improved dose distribution with a dry powder inhaler. One might expect a possible improvement in dose distribution from dry powder inhalers with similar particular size distributions to pressurized MDIs because the high velocity jet delivery of pressurized MDIs is absent in dry powder inhalers.…”

Section: B) Dry Powder Inhalersmentioning

confidence: 96%

Generation of Aerosolized Drugs

Wolff

Niven²

1994

Journal of Aerosol Medicine

View full text Add to dashboard Cite

The expanding use of inhalation therapy has placed demands on current aerosol generation systems that are difficult to meet with current inhalers. The desire to deliver novel drug entities such as proteins and peptides, as well as complex formulations including liposomes and microspheres, requires delivery systems of improved efficiency that will target the lung in a reproducible manner. These efforts have also been spurred by the phase out of chlorofluorocarbons (CFCs) and this has included a directed search for alternative propellants. Consequently, a variety of new aerosol devices and methods of generating aerosols are being studied. This includes the use of freon replacement propellants, dry powder generation systems, aqueous unit spray systems and microprocessor controlled technologies. Each approach has advantages and disadvantages depending upon each principle of action and set of design variables. In addition, specific drugs may be better suited for one type of inhaler device vs. another. The extent to which aerosol generation systems achieve their goals is discussed together with a summary of selected papers presented at the recent International Congress of Aerosols in Medicine.

show abstract

In Vitro and in Vivo Deposition of Drug Particles Inhaled from Pressurized Aerosol and Dry Powder Inhaler

Cited by 20 publications

References 9 publications

Inhalation therapy of equine respiratory disorders

Inhalation therapy of equine respiratory disorders

Performance-Modifying Influences in Dry Powder Inhalation Systems

Generation of Aerosolized Drugs

Contact Info

Product

Resources

About